We are delighted to share the results from Aon's 2023 Global Risk Management Survey (GRMS).
The GRMS collects and analyses business leaders' assessment of risk and risk management. The 2023 report is the ninth edition of the survey and the results from both Global and UK respondents reflect the increasingly interconnected nature of risk, with traditional business risks and people risks converging to create significant challenges for organisations.
|
Aon – Life Science Sector Specific Employee Benefits Survey:
Participating in this targeted survey can give you unique data insight to help:
The Cambridge Wide Open Day event on Wednesday 12th June is a unique opportunity for all to find out firsthand about the game-changing scientific advancements and technological innovations happening right here in our city, the UK’s science and tech capital.
The cream of Cambridge science and technology is opening its doors to participate in this year’s Be Curious event across the four main science clusters located in:
Produced using dry-spun 50 µm Collagen Type I fibers, AMSBIO has introduced the innovative CollaFibR™ additive proven to increase the shape fidelity and biological relevance of bioprinted constructs in hydrogels and bioinks.
In the field of personalized tissue engineering, 3D bioprinting shows immense promise, but the challenge lies in achieving both mechanical durability and biological relevance in the printed constructs.
SALT LAKE CITY, US and OXFORD, UK – 13 May 2024 – The leading US multi-specialty healthcare center, Metrodora Institute, and pioneering precision medicine company, PrecisionLife, announce the start of recruitment on a cohort of up to 1,000 patients into clinical trials to evaluate new diagnosis and treatment options for ME/CFS, Long Covid, and related disorders. The partners have developed genotypic diagnostic tests that are now being evaluated for their ability to provide clinicians with an accurate view of a patient’s risk of a specific disease.
Arecor Therapeutics plc
(“Arecor” or the “Company”)
ARECOR AND MEDTRONIC DIABETES ESTABLISH COLLABORATION TO DEVELOP A NOVEL THERMOSTABLE INSULIN FOR IMPLANTABLE PUMP DELIVERY
- Medtronic to fund Arecor’s development of Arestat™ enabled novel, high concentration, thermostable insulin, specifically tailored for use in combination with a next-generation implantable pump
DISCOVERY PARK BUSINESS A4P RECEIVES THE KING’S AWARD FOR ENTERPRISE IN INTERNATIONAL TRADE
The most prestigious business award in the United Kingdom.
A new report released today by Medicines Discovery Catapult (MDC), in partnership with the UK BioIndustry Association and the Association of the British Pharmaceutical Industry, highlights the impact of recent economic instability on companies in the life sciences sector.
The future health of patients depends on continuing to improve approaches to medicines discovery. However, barriers to investing in companies in the current economic climate threaten to prevent the UK from making some of its biggest breakthroughs.
Wondering how your company’s salary offers compare to your competitors? Are you offering above, or below industry standards? Is your business as diverse, inclusive and fair as it should be?
Or are you a STEM professional seeking to uncover salary trends and expectations for your role?
The exclusive insights from our Global STEM report not only offers the answers you're looking for, but also empowers you to make informed decisions for your career or recruitment strategy.